Search results
Results from the WOW.Com Content Network
Bezlotoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infections. By x-ray crystallized structure of N-terminal of TcdB, the toxin is identified to consist of three domains: a glucosyltransferase domain (GTD), a cysteine protease and a combined repetitive oligopeptide (CROP) domain.
The most well-characterized are enterotoxin (Clostridium difficile toxin A) and cytotoxin (Clostridium difficile toxin B), both of which may produce diarrhea and inflammation in infected people, although their relative contributions have been debated. [20] Toxins A and B are glucosyltransferases that target and inactivate the Rho family of GTPases.
Clostridioides difficile infects pigs, calves, and humans, and inhabits a natural reservoir of soil, faeces of domestic animals and humans, sewage, the human intestinal tract, and retail meat. [36] A 2015 CDC study estimated that C. diff afflicted almost half a million Americans and caused 29,000 deaths in 2011. The study estimated that 40% of ...
Clostridioides difficile toxin A (TcdA) is a toxin produced by the bacteria Clostridioides difficile, formerly known as Clostridium difficile. [1] It is similar to Clostridioides difficile Toxin B . The toxins are the main virulence factors produced by the gram positive , anaerobic, [ 2 ] Clostridioides difficile bacteria.
A unit of selection is a biological entity within the hierarchy of biological organization (for example, an entity such as: a self-replicating molecule, a gene, a cell, an organism, a group, or a species) that is subject to natural selection. There is debate among evolutionary biologists about the extent to which evolution has been shaped by ...
The general selection model (GSM) is a model of population genetics that describes how a population's allele frequencies will change when acted upon by natural selection. [ 1 ] [ better source needed ]
The variation affects the speed and rate of evolutionary change through the selection and modulation of phenotypic variations. [28] Ultimately, this results in a lower amount of diversity observed throughout evolution, as the majority of phenotypes do not persist beyond a few generations due to their inferior morphology, biochemical makeup, or ...
In this subset, the patients receiving bezlotoxumab appeared to have a higher rate of negative outcomes than the placebo group, although there may have been an imbalance in how sick the patients in those groups were. [11] [12] [13] Bezlotoxumab was approved for medical use in the United States in October 2016. [3] [14] [15] [16]